Evidence map›Paper›PMID 26578313›Full record

ReviewJournal of industrial microbiology & biotechnology2016

Integrating mass spectrometry and genomics for cyanobacterial metabolite discovery.

Nathan A Moss, Matthew J Bertin, Karin Kleigrewe, Tiago F Leão, Lena Gerwick, William H Gerwick

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of industrial microbiology & biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Gifted microbes for genome mining and natural product discovery.Journal of industrial microbiology & biotechnology · 2017
    Review
  7. Comparative genomics uncovers the prolific and distinctive metabolic potential of the cyanobacterial genusProceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nathan A MossCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA. namoss@ucsd.edu.
Matthew J BertinCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA.
Karin KleigreweCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA.
Tiago F LeãoCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA.
Lena GerwickCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA.
William H GerwickCenter for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, 9500 Gilman Drive MC0212, La Jolla, CA, 92093, USA. wgerwick@ucsd.edu.
University of California, San Diego · USScripps Institution of Oceanography · US

Funding

Unified Computation Tools for Natural Products ResearchR01GM107550 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COTTRELL, GARRISON W, GERWICK, WILLIAM HENRY · 2013 to 2025
$8.2M
Biosynthetic Analysis of Marine Cyanobacterial PathwaysR01CA108874 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GERWICK, WILLIAM HENRY, SHERMAN, DAVID H · 2006 to 2015
$3.4M
Training Program in Marine BiotechnologyT32GM067550 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GERWICK, WILLIAM HENRY · 2004 to 2019
$2.0M
NCI NIH HHS CA108874NCI NIH HHS R01 CA108874NIGMS NIH HHS GM107550-01NIGMS NIH HHS R01 GM107550NIGMS NIH HHS T32 GM067550
6 · The paper itself

Abstract

Filamentous marine cyanobacteria produce bioactive natural products with both potential therapeutic value and capacity to be harmful to human health. Genome sequencing has revealed that cyanobacteria have the capacity to produce many more secondary metabolites than have been characterized. The biosynthetic pathways that encode cyanobacterial natural products are mostly uncharacterized, and lack of cyanobacterial genetic tools has largely prevented their heterologous expression. Hence, a combination of cutting edge and traditional techniques has been required to elucidate their secondary metabolite biosynthetic pathways. Here, we review the discovery and refined biochemical understanding of the olefin synthase and fatty acid ACP reductase/aldehyde deformylating oxygenase pathways to hydrocarbons, and the curacin A, jamaicamide A, lyngbyabellin, columbamide, and a trans-acyltransferase macrolactone pathway encoding phormidolide. We integrate into this discussion the use of genomics, mass spectrometric networking, biochemical characterization, and isolation and structure elucidation techniques.

Indexed as

GenomicsMass SpectrometryBiological ProductsBiosynthetic PathwaysCyanobacteriaHumansSecondary MetabolismBiological ProductsBiosynthesisCyanobacteriaGenomicsMass spectrometryNatural products

Identifiers

PMID26578313
PMCPMC5065021
OpenAlexW2178128380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.